EA007954B1 - Фармацевтическая препаративная форма, включающая мелатонин - Google Patents
Фармацевтическая препаративная форма, включающая мелатонин Download PDFInfo
- Publication number
- EA007954B1 EA007954B1 EA200401331A EA200401331A EA007954B1 EA 007954 B1 EA007954 B1 EA 007954B1 EA 200401331 A EA200401331 A EA 200401331A EA 200401331 A EA200401331 A EA 200401331A EA 007954 B1 EA007954 B1 EA 007954B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- melatonin
- zolpidem
- drug
- sleep
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL149377A IL149377A (en) | 2002-04-28 | 2002-04-28 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| PCT/IL2003/000240 WO2003086352A1 (en) | 2002-04-08 | 2003-03-20 | Pharmaceutical formulation comprising melatonin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200401331A1 EA200401331A1 (ru) | 2005-04-28 |
| EA007954B1 true EA007954B1 (ru) | 2007-02-27 |
Family
ID=29227410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200401331A EA007954B1 (ru) | 2002-04-28 | 2003-03-20 | Фармацевтическая препаративная форма, включающая мелатонин |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20050175692A1 (enExample) |
| EP (1) | EP1494650B1 (enExample) |
| JP (1) | JP2005527583A (enExample) |
| KR (1) | KR101000624B1 (enExample) |
| CN (1) | CN100386070C (enExample) |
| AR (1) | AR039232A1 (enExample) |
| AT (1) | ATE507831T1 (enExample) |
| AU (1) | AU2003227304B2 (enExample) |
| BR (1) | BR0308762A (enExample) |
| CA (1) | CA2477516C (enExample) |
| DE (1) | DE60336999D1 (enExample) |
| DK (1) | DK1494650T3 (enExample) |
| EA (1) | EA007954B1 (enExample) |
| ES (1) | ES2366116T3 (enExample) |
| GT (1) | GT200300064A (enExample) |
| HN (1) | HN2003000115A (enExample) |
| IL (1) | IL149377A (enExample) |
| IS (1) | IS2858B (enExample) |
| MX (1) | MXPA04009893A (enExample) |
| NO (1) | NO332525B1 (enExample) |
| NZ (1) | NZ536298A (enExample) |
| PE (1) | PE20040161A1 (enExample) |
| PL (1) | PL209922B1 (enExample) |
| PT (1) | PT1494650E (enExample) |
| TW (1) | TW200305404A (enExample) |
| UA (1) | UA86924C2 (enExample) |
| UY (1) | UY27753A1 (enExample) |
| WO (1) | WO2003086352A1 (enExample) |
| ZA (1) | ZA200407563B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1696959A2 (en) * | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
| TW200626137A (en) * | 2004-12-13 | 2006-08-01 | Takeda Pharmaceuticals Co | Preventive or therapeutic agent for sleep disorder |
| US20060198872A1 (en) * | 2005-03-07 | 2006-09-07 | Chioma Ikonte | Plant based dietary supplement for improving the duration and quality of sleep |
| KR20070070307A (ko) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | 수면 개선 의약 조성물 |
| CN1299680C (zh) * | 2005-08-29 | 2007-02-14 | 陈彦方 | 一种治疗失眠的黑白制剂 |
| AR056076A1 (es) * | 2005-09-20 | 2007-09-19 | Takeda Pharmaceutical | Agente profilactico o terapeutico para el desorden de sueno |
| CN102018681A (zh) * | 2010-12-10 | 2011-04-20 | 荣港生技医药科技(北京)有限公司 | 一种美乐托宁缓释剂、其制备方法及其应用 |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US9532952B2 (en) * | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| EP2570126B1 (en) * | 2011-09-16 | 2014-03-26 | Darius Rassoulian | Use of melatonin for treating acute alcohol intoxication |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| MX386987B (es) * | 2016-10-31 | 2025-03-19 | Neurim Pharma 1991 | Mini-tabletas de melatonina y métodos de fabricación de las mismas. |
| CN109364031A (zh) * | 2018-10-07 | 2019-02-22 | 威海贯标信息科技有限公司 | 一种盐酸曲唑酮片剂组合物 |
| US20230045118A1 (en) * | 2020-01-17 | 2023-02-09 | Societe Des Produits Nestle S.A. | Dosage form with sustained release melatonin pellets |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034105A (en) * | 1996-07-17 | 2000-03-07 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
| US6274635B1 (en) * | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| US5707652A (en) * | 1990-12-04 | 1998-01-13 | State Of Oregon | Methods of treating circadian rhythm phase disorders |
| IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
| FR2718020B1 (fr) * | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
| JP4516159B2 (ja) * | 1995-02-01 | 2010-08-04 | ニューリム ファーマシューティカルズ(1991)リミテッド | 薬物嗜癖患者の治療のためのメラトニンの使用 |
| KR100494214B1 (ko) * | 1996-03-08 | 2005-11-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 삼환화합물,그의제조방법및용도 |
| US5849338A (en) * | 1996-04-10 | 1998-12-15 | Chronorx Llc | Unit dosage forms for treatment of vasoconstriction and related conditions |
| EP1100508B8 (en) * | 1998-06-09 | 2004-01-07 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders |
| CN1131030C (zh) * | 1999-03-18 | 2003-12-17 | 胡秀云 | 一种由褪黑素和安定制成的调节睡眠的组合物 |
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
-
2002
- 2002-04-28 IL IL149377A patent/IL149377A/en active IP Right Grant
-
2003
- 2003-03-17 GT GT200300064A patent/GT200300064A/es unknown
- 2003-03-20 MX MXPA04009893A patent/MXPA04009893A/es active IP Right Grant
- 2003-03-20 DK DK03746393.2T patent/DK1494650T3/da active
- 2003-03-20 PT PT03746393T patent/PT1494650E/pt unknown
- 2003-03-20 CN CNB038075644A patent/CN100386070C/zh not_active Expired - Lifetime
- 2003-03-20 KR KR1020047015934A patent/KR101000624B1/ko not_active Expired - Lifetime
- 2003-03-20 JP JP2003583375A patent/JP2005527583A/ja active Pending
- 2003-03-20 WO PCT/IL2003/000240 patent/WO2003086352A1/en not_active Ceased
- 2003-03-20 UA UA20041008558A patent/UA86924C2/ru unknown
- 2003-03-20 EA EA200401331A patent/EA007954B1/ru not_active IP Right Cessation
- 2003-03-20 DE DE60336999T patent/DE60336999D1/de not_active Expired - Lifetime
- 2003-03-20 AU AU2003227304A patent/AU2003227304B2/en not_active Expired
- 2003-03-20 ES ES03746393T patent/ES2366116T3/es not_active Expired - Lifetime
- 2003-03-20 CA CA2477516A patent/CA2477516C/en not_active Expired - Lifetime
- 2003-03-20 NZ NZ536298A patent/NZ536298A/en not_active IP Right Cessation
- 2003-03-20 EP EP03746393A patent/EP1494650B1/en not_active Expired - Lifetime
- 2003-03-20 AT AT03746393T patent/ATE507831T1/de active
- 2003-03-20 US US10/510,625 patent/US20050175692A1/en not_active Abandoned
- 2003-03-20 PE PE2003000278A patent/PE20040161A1/es not_active Application Discontinuation
- 2003-03-20 PL PL372867A patent/PL209922B1/pl unknown
- 2003-03-20 BR BR0308762-0A patent/BR0308762A/pt not_active Application Discontinuation
- 2003-04-01 TW TW092107377A patent/TW200305404A/zh unknown
- 2003-04-02 AR ARP030101156A patent/AR039232A1/es not_active Application Discontinuation
- 2003-04-07 UY UY27753A patent/UY27753A1/es not_active Application Discontinuation
- 2003-04-07 HN HN2003000115A patent/HN2003000115A/es unknown
-
2004
- 2004-08-27 NO NO20043576A patent/NO332525B1/no not_active IP Right Cessation
- 2004-09-21 ZA ZA2004/07563A patent/ZA200407563B/en unknown
- 2004-10-07 IS IS7492A patent/IS2858B/is unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034105A (en) * | 1996-07-17 | 2000-03-07 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
| US6274635B1 (en) * | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wagner et al. | Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia | |
| Charney et al. | Hypnotics and sedatives | |
| JP5646126B2 (ja) | 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法 | |
| Mihic et al. | Hypnotics and sedatives | |
| JP2007517040A (ja) | 睡眠の質を改善するためのメラトニン併用療法 | |
| CA2477516C (en) | Pharmaceutical formulation comprising melatonin | |
| JP2007522200A (ja) | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ | |
| EP0724878B1 (en) | Use of melatonin for treating patients suffering from drug dependencies | |
| US6344487B1 (en) | Treatment of insomnia | |
| TW483757B (en) | A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs | |
| Dailey | Sedative-hypnotic and anxiolytic drugs | |
| FUNCTIONING | SLEEP MORE! | |
| HK1075616B (en) | Pharmaceutical formulation comprising melatonin | |
| CA2211839C (en) | Use of melatonin for treating patients suffering from drug addiction | |
| Monti et al. | Role of zolpidem in the management of primary and comorbid insomnia | |
| Singh et al. | Pharmacotherapeutic options for treatment of insomnia | |
| MXPA97005856A (en) | Use of melatonine in the manufacture of unmedicament to deal with addiction to dro | |
| HK1001218B (en) | Use of melatonin for treating patients suffering from drug dependencies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |